Based on the beneficial therapeutic profile of SGLT2 inhibitors and the experience of their use in non-hospitalised patients, we aimed to retrospectively analyse the glycaemic and clinical efficacy and safety of empagliflozin continuation in combination with basal insulin compared to a basal-bolus insulin regimen in patients with T2D hospitalised for acute decompensated HF. Here, INS is linked to type 2 diabetes mellitus.